Detalles de la búsqueda
1.
Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.
N Engl J Med
; 386(21): 1973-1985, 2022 05 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-35403841
2.
Plain language summary of the CheckMate 816 study results: nivolumab plus chemotherapy given before surgery for non-small-cell lung cancer.
Future Oncol
; 19(8): 549-557, 2023 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-36815433
3.
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
N Engl J Med
; 373(17): 1627-39, 2015 Oct 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-26412456
4.
Endothelial-dependent vasomotion in a coronary segment treated by ABSORB everolimus-eluting bioresorbable vascular scaffold system is related to plaque composition at the time of bioresorption of the polymer: indirect finding of vascular reparative therapy?
Eur Heart J
; 33(11): 1325-33, 2012 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-22507972
5.
The SPIRIT V diabetic study: a randomized clinical evaluation of the XIENCE V everolimus-eluting stent vs the TAXUS Liberté paclitaxel-eluting stent in diabetic patients with de novo coronary artery lesions.
Am Heart J
; 163(5): 867-875.e1, 2012 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-22607866
6.
ABSORB II randomized controlled trial: a clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatment of subjects with ischemic heart disease caused by de novo native coronary artery lesions: rationale and study design.
Am Heart J
; 164(5): 654-63, 2012 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-23137495
7.
A comparative assessment by optical coherence tomography of the performance of the first and second generation of the everolimus-eluting bioresorbable vascular scaffolds.
Eur Heart J
; 32(3): 294-304, 2011 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-21123276
8.
Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes.
Circulation
; 122(22): 2301-12, 2010 Nov 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-21098436
9.
Evaluation of the XIENCE V everolimus eluting coronary stent system in the Asian population of the SPIRIT V single arm study. 2-year clinical follow-up data.
Indian Heart J
; 63(5): 402-8, 2011.
Artículo
en Inglés
| MEDLINE | ID: mdl-23550416
10.
A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods.
Lancet
; 373(9667): 897-910, 2009 Mar 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-19286089
11.
IVUS radiofrequency analysis in the evaluation of the polymeric struts of the bioabsorbable everolimus-eluting device during the bioabsorption process.
Catheter Cardiovasc Interv
; 75(6): 914-8, 2010 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-20091822
12.
Efficacy of everolimus eluting stent implantation in patients with calcified coronary culprit lesions: two-year angiographic and three-year clinical results from the SPIRIT II study.
Catheter Cardiovasc Interv
; 76(5): 634-42, 2010 Nov 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-20690152
13.
CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer.
J Clin Oncol
; 36(28): 2836-2844, 2018 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30110194
14.
Effectiveness of "direct" stenting without balloon predilatation (from the Multilink Tetra Randomised European Direct Stent Study [TRENDS]).
Am J Cardiol
; 97(3): 316-21, 2006 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-16442388
15.
The ABSORB EXTEND study: preliminary report of the twelve-month clinical outcomes in the first 512 patients enrolled.
EuroIntervention
; 10(12): 1396-401, 2015 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-24769555
16.
Circumferential distribution of the neointima at six-month and two-year follow-up after a bioresorbable vascular scaffold implantation: a substudy of the ABSORB Cohort B Clinical Trial.
EuroIntervention
; 10(11): 1299-306, 2015 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-24769420
17.
Procedural and clinical outcomes of the Absorb everolimus-eluting bioresorbable vascular scaffold: one-month results of the Bioresorbable vascular Scaffold Evaluated At Rotterdam Cardiology Hospitals (B-SEARCH).
EuroIntervention
; 10(2): 236-40, 2014 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-23999210
18.
1-year clinical outcomes of diabetic patients treated with everolimus-eluting bioresorbable vascular scaffolds: a pooled analysis of the ABSORB and the SPIRIT trials.
JACC Cardiovasc Interv
; 7(5): 482-93, 2014 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-24746650
19.
Dynamics of vessel wall changes following the implantation of the absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study at 6, 12, 24 and 36 months.
EuroIntervention
; 9(11): 1271-84, 2014 Mar 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-24291783
20.
Effect of the endothelial shear stress patterns on neointimal proliferation following drug-eluting bioresorbable vascular scaffold implantation: an optical coherence tomography study.
JACC Cardiovasc Interv
; 7(3): 315-24, 2014 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-24529931